Prostate neoplasm

This early-phase study tests a personalized vaccine made from a patient's own immune cells and tumor markers. It aims to help the immune system attack advanced prostate cancer that has stopped responding to standard treatments. About 9 to 18 men will receive four doses over eight…

This phase 3 trial is testing whether adding the drug niraparib to standard therapy (abiraterone and prednisone) can slow cancer growth in men with metastatic castration-sensitive prostate cancer who have specific inherited or tumor gene mutations. About 700 participants are bein…

This phase 3 trial tests a radioactive drug called 177Lu-PSMA-617 in 469 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers compare it to switching to another hormone th…

This study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants took ei…

This phase 3 trial tests whether adding apalutamide to standard treatment (abiraterone and prednisone) can delay cancer growth in men with advanced prostate cancer that no longer responds to hormone therapy. About 982 participants who have not had chemotherapy are randomly assign…

This study looks at how the body absorbs different versions of two prostate cancer drugs, niraparib and abiraterone acetate, taken together with prednisone. It involves 136 men with metastatic castration-resistant prostate cancer. The goal is to compare the absorption of various …

This phase 3 study tests whether adding the drug apalutamide to standard radiotherapy and hormone therapy can delay cancer spread or death in 692 men with high-risk prostate cancer. Participants are randomly assigned to receive either the standard treatment alone or with apalutam…

This study tests whether adding apalutamide to standard hormone therapy before and after prostate removal surgery can improve outcomes for men with high-risk prostate cancer. About 2,500 participants will receive either the drug combination or a placebo. The goal is to see if the…

This early-stage study tests the drug apalutamide in 19 Chinese men whose prostate cancer has spread and no longer responds to hormone therapy. Researchers want to see how the drug behaves in the body and if it is safe. They will also check if it lowers PSA levels, a marker of ca…

This phase 3 trial tests whether adding apalutamide (a hormone-blocking drug) to standard hormone therapy and radiation can delay the spread of prostate cancer in high-risk patients. About 1,500 men with localized or locally advanced prostate cancer are participating. The main go…

This study tests a new drug called JNJ-56021927 combined with abiraterone acetate (Zytiga) and prednisone in 57 men with metastatic castration-resistant prostate cancer. The goal is to see how these drugs interact, check safety, and get an early look at effectiveness. All partici…

This early-phase study tests a new drug, JNJ-69086420, that delivers a radioactive particle directly to prostate cancer cells. The trial involves about 144 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals ar…

This pilot study is testing a device that uses ultrasound images to guide a laser or freezing probe directly into prostate tumors. The goal is to destroy only the cancerous tissue while sparing healthy areas. Thirty men with low- to intermediate-risk prostate cancer that hasn't s…

This early-stage study tests a new drug, JNJ-78278343, that helps the body's immune T-cells find and attack prostate cancer cells. It involves 216 men with advanced prostate cancer that has spread. The main goals are to find the safest and most effective dose and to monitor side …

This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…

This study tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy can help men whose prostate cancer has spread but still responds to hormones. About 1,140 men are taking part. The goal is to see if the combination slows cancer growth and exte…

This phase 3 trial tests whether adding enzalutamide to standard hormone therapy and radiation can delay cancer spread in 802 men with high-risk localized prostate cancer. Participants receive either enzalutamide or a conventional anti-androgen alongside hormone therapy and radia…

This trial compares two common radiotherapy schedules for prostate cancer: 70 Gy in 28 sessions versus 60 Gy in 20 sessions. Both are already used in clinics, but it is not clear which one works better or causes fewer side effects. The study involves 400 men with early-stage pros…

This phase II trial tests whether adding the immunotherapy drug durvalumab to precise radiation (SBRT) can better control prostate cancer that has returned and spread to a few spots (oligometastases). About 96 men with hormone-sensitive prostate cancer will be randomly assigned t…

This study provides early access to apalutamide for men whose prostate cancer has stopped responding to standard hormone therapy but has not yet spread. The goal is to gather more safety information while offering treatment before the drug is widely available. Participants must c…

This phase 3 trial compares a new, shorter course of radiation (ultra-hypofractionated) to the standard longer course for men with prostate cancer that has spread to lymph nodes. Both groups also receive a brachytherapy boost and hormone therapy. The study aims to see if the shor…

This study tests whether MR-guided cryoablation—a procedure that freezes tumors—can effectively treat prostate cancer that has come back in the prostate bed. Researchers are enrolling 107 patients whose tumors are small and not suitable for surgery or radiation. The goal is to se…

Researchers at Herlev Hospital are studying whether multiparametric MRI can help doctors decide which men with low-risk prostate cancer can safely stay on active surveillance instead of getting treatment. The trial enrolls 150 men with newly diagnosed low-risk prostate cancer who…

This study is testing whether a special type of MRI (multiparametric MRI) can better identify which men with low-risk prostate cancer can safely delay treatment. About 200 men already on active surveillance will receive the MRI, and if suspicious areas are found, they will get ad…

This study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measur…

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …

This study is testing whether a type of PET scan called PSMA PET is more accurate than standard scans (like CT or bone scans) for monitoring prostate cancer. About 58 men with progressive prostate cancer will receive an injection of a radioactive tracer and then undergo PET/CT im…

This trial evaluates a new imaging technique called 18F-PSMA-1007 PET/CT for detecting prostate cancer in men with elevated PSA levels (4-20 ng/mL) or abnormal rectal exams. The scan uses a radioactive tracer that targets a protein common on prostate cancer cells, aiming to impro…

This study looks at whether eating more omega-3 fatty acids (like those in fish oil) and taking a drug called dutasteride can slow the growth of low-risk prostate cancer. The 120 participants are men on active surveillance, meaning their cancer is being watched rather than treate…

This study tests a personalized rehabilitation program designed to help men recover their sexual quality of life after prostate removal for cancer. About 135 men will take part, with half receiving the program and half receiving standard care. The goal is to see if the program im…

This study aimed to see if a 12-week supervised exercise program could improve quality of life and physical fitness in men with advanced prostate cancer receiving hormone therapy. Participants would have been randomly assigned to either the supervised program or usual care with e…

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find tumors that are hard to see on CT scans. About 3,900 adults with certain cancers or growths will have their biopsy or ablation procedure done using this smart needle. The g…

This study aims to find better ways to detect prostate cancer by looking at blood samples. Researchers will test special antibodies to see if they can identify cancer markers in circulating tumor cells. The study includes 40 men with prostate cancer and 20 healthy donors. It is a…

This study collects blood and saliva samples from people with cancer and their relatives to build a DNA bank. Researchers hope to better understand how cancer runs in families. About 992 participants are expected to join. The samples will be stored and analyzed later for genetic …